Shipment of hydroxychloroquine from India reaches the US. USA

WASHINGTON: A shipment from India arrived in the United States on Saturday, days after New Delhi lifted the ban on exporting the antimalarial drug, seen as a possible cure for COVID-19, to the US. USA And to other countries for humanitarian purposes gardens.

>

Earlier this week, India, at the request of President Donald Trump, authorized the export of 35.82 lakh hydroxychloroquine tablets to the US. USA Along with nine metric tons of active pharmaceutical ingredient or API required in manufacturing the drug.

Supporting our partners in the fight against COVID-19. The shipment of hydroxychloroquine from India arrived at Newark airport today, the Indian ambassador to the United States, Taranjit Singh Sandhu, tweeted.

Trump, during a phone call last week, asked Prime Minister Narendra Modi to lift control of the U.S. anti-malaria drug order, of which India is the leading producer. India, which makes 70 percent of the world's supply of hydroxychloroquine, lifted the ban on April 7.

Hydroxychloroquine has been identified as a possible treatment for COVID-19 by the United States Food and Drug Administration and is being tested in more than 1,500 patients in NY .

Anticipating that it will work, given the initial positive results, Trump has purchased more than 29 million doses of hydroxychloroquine for the potential treatment of patients with COVID-19.

The arrival of consignment was welcomed by Americans. "US will never forget this great humanitarian gesture by India . Under President Trump and Prime Minister Narendra Modi, the two largest democracies of the world have come together than ever in the past,” said NY -based Al Mason, a real estate consultant and a Trump supporter.

A wonderful gesture from India to her friends in need, Dr. Sampat Shivangi tweeted. Describing this as a wonderful gesture, Steve Filipovic, who works in the construction industry, thanked the Ambassador of India.

Meanwhile, according to a new French study of 1,061 hospitalized patients with COVID-19 showed a 91.7 percent cure (viral clearance) within 10 days of hydroxychloroquine treatment along with antibiotics. It also reported a 96 percent cure rate after 15 days.

Earlier this week, the National Institute of Health reported that a clinical trial began to evaluate the safety and efficacy of hydroxychloroquine for treating hospitalized adults with coronavirus disease 2019 (COVID-19), with the first participants now enrolled in Tennessee.

Hydroxychloroquine is used to treat malaria and rheumatoid conditions such as arthritis. In several studies, the drug has demonstrated antiviral activity, an ability to modify the activity of the immune system, and has an established safety profile at appropriate doses, leading to the hypothesis that it may also be useful in the treatment of COVID- 19. NIH said.

The drug is not without risk, as even short-term use can cause cardiac arrhythmias, seizures, dermatological reactions and hypoglycemia, he added.

Many US hospitals USA They are currently using hydroxychloroquine as a first-line therapy for hospitalized patients with COVID-19 despite extremely limited clinical data supporting its efficacy, said Wesley Self, an emergency medicine physician at Vanderbilt University Medical Center and a researcher with the Network. of PETAL clinical trials that leads the ORCHID Test.

Therefore, data on hydroxychloroquine for the treatment of COVID-19 is urgently needed to inform clinical practice, he added.

According to the NIH, participants will be randomly assigned to receive 400 mg of hydroxychloroquine twice daily for two doses (day one), then 200 mg twice daily for the subsequent eight doses (days two to five) or a placebo twice. daily for five days.

COVID-19 cases were first identified in December 2019 in Hubei province, China.

As of Saturday, more than 16 lakh people worldwide have tested positive and more than one lakh has died. The United States has become the access point with 20,000 deaths and 5.3 lakh cases

>

comments